Pharmaceuticals > Industries > Ernst & Young - Ernst & Young - Korea

How can you manage your company through the recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified some overarching themes. From managing risks to improving capital allocation, we reveal the lessons that could mean the difference between surviving and thriving in the new economic environment.

How are life sciences companies weathering the financial crisis? Working with the Economist Intelligence Unit, we surveyed executives on the steps they’re taking to contend with their ever-mounting pressures. While the industry faced strong headwinds before the economic downturn, our findings highlight key transformational issues and confirm the crisis intensified the need for change. Discover which strategic responses are topping their agendas and see how yours compare (pdf, 281kb).

As Washington changes direction, many question whether reform policies will present new opportunities or risks for the pharma, biotech, and medtech sectors. Watch our webcast to hear the views of industry leaders, including Billy Tauzin, President of PhRMA, Jim Greenwood, President of the Biotechnology Industry Organization and Brett Loper, Senior Executive Vice President, Government Affairs from AdvaMed.

With today’s economic turmoil, financial viability of some suppliers may be at risk. As pharmaceutical companies rely on an increasingly complex "extraprise" of suppliers, monitoring suppliers' financial health and identifying warning signs will be critical. Even well-run suppliers may experience discontinued credit or other liquidity challenges. And demise may be quick – in weeks or even days. Discover measures for monitoring risk and protecting stakeholder value (pdf, 82kb).